ABMC Receives FDA Clearance on Its Rapid Reader; Clearance is the First for an All-Inclusive Drug Screen Interpretation & Data Management System.

KINDERHOOK, N.Y. -- American Bio Medica Corporation (NASDAQ:ABMC) announced today that the US Food and Drug Administration (FDA) has granted the Company 510(k) clearance on its Rapid Reader(TM), a personal computer peripheral that interprets, scans, transmits, records and stores the results of ABMC drug screens. This is the first all-inclusive drug screen result interpretation and data management system that has received 510(k) clearance from FDA. The clearance allows ABMC to provide the Rapid Reader to customers in clinical markets.

ABMC Chief Executive Officer Stan Cipkowski stated, "This clearance is an important milestone and represents our commitment to providing all of our customers with the most innovative quality products and support systems on the market today. Now, even clinical customers can benefit from the Rapid Reader's user-friendly result interpretation and secure electronic storing and sharing capabilities." Cipkowski added, "Many non-clinical customers prefer to utilize devices that are FDA-cleared; we believe now that the Rapid Reader has received such clearance, it will be more widely received in our non-clinical markets as well."

The Rapid Reader is a compact, portable device that, when connected to any computer, captures a picture of the test results on an ABMC drug screen using a high resolution camera. The Rapid Reader's proprietary software analyzes this image and interprets the results. The information is then sent to a data management system, which enables the user to interpret, store, transmit and print the drug test results. The Rapid Reader system can only be used to interpret and record the results of ABMC drug screens.

For more information on ABMC or its drug testing products, please visit www.abmc.com

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen(R), Rapid One(R), Rapid TEC(R) and RDS(R) InCup(TM) products test for the presence or absence of drugs of abuse in urine, while OralStat(R) tests for the presence or absence of drugs of abuse in oral fluids.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2004, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.